Last €24.92 EUR
Change Today -0.68 / -2.66%
Volume 0.0
CDG On Other Exchanges
As of 9:42 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (CDG) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/13 - €29.87
52 Week Low
01/7/14 - €20.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acorda therapeutics inc (CDG) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (CDG) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company’s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for the treatment of injuries to the brain and spinal cord, as well as other neurotraumatic indications. The company was founded in 1995 and is headquartered in Ardsley, New York.

421 Employees
Last Reported Date: 03/3/14
Founded in 1995

acorda therapeutics inc (CDG) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $1.3M
Chief of Business Operations
Total Annual Compensation: $420.4K
General Counsel, Corporate Secretary and Pres...
Total Annual Compensation: $773.5K
Chief Medical Officer
Total Annual Compensation: $570.9K
Chief Scientific Officer
Total Annual Compensation: $576.9K
Compensation as of Fiscal Year 2012.

acorda therapeutics inc (CDG) Key Developments

Acorda Therapeutics, Inc. to Resume Recruitment for Phase 1b Clinical Trial of GGF2

In October 2013, Acorda Therapeutics, Inc. initiated the second clinical trial of GGF2 for the treatment of heart failure and subsequently paused enrollment in the trial to review additional preclinical data. On April 22, 2014, the company announced that it has completed its review of these data and has agreed with the Food and Drug Administration (FDA) that the Phase 1b clinical trial of GGF2 will resume recruitment. The single-intravenous infusion trial is assessing tolerability of three dose levels of GGF2 and also includes several exploratory efficacy measures. The company expects that the trial will be completed in 2015.

Acorda Therapeutics, Inc. Announces Initiation of Its Phase 3 Study of dalfampridine-QD

On April 14, 2014, Acorda Therapeutics, Inc. announced that the initiation of its Phase 3 study of dalfampridine-QD in people with post-stroke walking deficits will begin in the second half of 2014; previously the Company had projected study initiation in the second quarter of 2014. The developer of the once-daily, or QD, formulation has informed the Company of an alcohol dose dumping finding in vitro and the company will need to perform a short clinical study to determine whether this also exists in vivo. The clinical study will be conducted in healthy volunteers and is expected to be completed in the third quarter of 2014.

Acorda Therapeutics, Inc. to Expand Corporate Footprint in Ardsley

Acorda Therapeutics, Inc. will expand its corporate footprint in Ardsley. The biotech company has expanded its operations and plans to occupy approximately 25,500 of additional square feet at 440 Saw Mill River Road, in addition to its current 130,000 square-foot space at 410-420 Saw Mill River Road. The expanded space will accommodate approximately 90 new permanent employees that the company anticipates hiring over the next five years. In addition, approximately 35 to 45 full-time construction jobs are expected to be required to complete the four to six month project. The new jobs will be high-skill, high-wage biotechnology-related positions such as drug-safety specialists, researchers, quality-assurance staff and market-development professionals. Acorda's new space will include additional offices, a call center and training facilities. The IDA acted to grant Acorda an exemption from 7.375% sales tax on $3.8 million in capital improvement costs, furniture and equipment for the duration of the construction process. Renovations are expected to begin by August 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDG:GR €24.92 EUR -0.68

CDG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $296.35 USD -10.40
Novartis AG SFr.74.80 CHF -1.45
Teva Pharmaceutical Industries Ltd $50.21 USD -0.46
View Industry Companies

Industry Analysis


Industry Average

Valuation CDG Industry Range
Price/Earnings 89.4x
Price/Sales 4.3x
Price/Book 3.3x
Price/Cash Flow 88.6x
TEV/Sales 3.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at